CardiologyDapagliflozinLDL catabolism
Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing
By MedXY|Jul 31, 2026
This study demonstrates that dapagliflozin does not impair LDL catabolism but favorably shifts VLDL1 and VLDL2 catabolism toward normal physiology in type 2 diabetes, potentially contributing to reduced atherosclerosis risk.
